+

WO2007016953A1 - Composition réduisant les risques de cancer du foie induit par l’alcool - Google Patents

Composition réduisant les risques de cancer du foie induit par l’alcool Download PDF

Info

Publication number
WO2007016953A1
WO2007016953A1 PCT/EP2005/009151 EP2005009151W WO2007016953A1 WO 2007016953 A1 WO2007016953 A1 WO 2007016953A1 EP 2005009151 W EP2005009151 W EP 2005009151W WO 2007016953 A1 WO2007016953 A1 WO 2007016953A1
Authority
WO
WIPO (PCT)
Prior art keywords
food composition
dietary supplementation
dose
alcohol
supplementation according
Prior art date
Application number
PCT/EP2005/009151
Other languages
English (en)
Inventor
Markus Graf V. Matuschka-Greiffenclau
Original Assignee
Matuschka-Greiffenclau Markus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matuschka-Greiffenclau Markus filed Critical Matuschka-Greiffenclau Markus
Priority to DK06762860.2T priority Critical patent/DK1909600T3/da
Priority to AT06762860T priority patent/ATE554663T1/de
Priority to PCT/EP2006/007466 priority patent/WO2007017139A1/fr
Priority to AU2006278823A priority patent/AU2006278823B2/en
Priority to EP06762860A priority patent/EP1909600B1/fr
Priority to CA2611389A priority patent/CA2611389C/fr
Priority to ES06762860T priority patent/ES2386460T3/es
Priority to KR20137031344A priority patent/KR101487848B1/ko
Priority to US11/997,127 priority patent/US8580750B2/en
Priority to JP2008523251A priority patent/JP5371428B2/ja
Priority to KR1020077028054A priority patent/KR101562271B1/ko
Priority to UAA200800602A priority patent/UA94713C2/uk
Priority to PL06762860T priority patent/PL1909600T3/pl
Priority to EA200800427A priority patent/EA012753B1/ru
Priority to PT06762860T priority patent/PT1909600E/pt
Priority to SI200631337T priority patent/SI1909600T1/sl
Publication of WO2007016953A1 publication Critical patent/WO2007016953A1/fr
Priority to HK08110628.1A priority patent/HK1117709A1/xx
Priority to HRP20120489TT priority patent/HRP20120489T1/hr
Priority to JP2013091972A priority patent/JP5785581B2/ja
Priority to US14/058,388 priority patent/US9402849B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention is directed to a composition, in particular a food composition, or dietary supplementation, which is active in respect to a reduction of alcohol or drug induced liver cancer rise.
  • the invention is directed to a composition affecting the moderation of a drug, in particular alcohol degradation process within the human body.
  • an object of the present invention is to achieve solutions which provide a reduction in the toxic effects or physiological stress in connection with the consumption of drugs, in particular alcohol, in particular for people with a predisposition towards rapid alcohol degradation and subsequent accumulation of acetaldehyde due to a genetic polymorphism of human acetaldehyde-dehydrogenase enzym.
  • Ethanol taken into the body is eliminated by its oxidation mainly in the liver.
  • Ethanol is first metabolised to acetaldehyde by alcohol dehydrogenase (ADH), and then acetaldehyde is further metabolised to acetic acid by aldehyde dehydrogenase (ALDH).
  • ADH alcohol dehydrogenase
  • ALDH aldehyde dehydrogenase
  • the first metabolite of orally ingested alcohol, acetaldehyde is suspected to play a pivotal role in the development of alcohol related cancers because of its established DNA damaging effects (single-strand and double-strand breaks) and carcinogenicity in laboratory animals.
  • acetaldehyde can damage the culture hepatocytes and results in secondary hyperproliferation .
  • ALDH2 class 2 ALDH
  • a mutant allele ALDH2*2 has a single point mutation (G- »A) in exon 12 of the active ALDH2*1 gene. This mutation is expected to result in a substitution of glutamic acid (GIu) at amino acid position 487 by lysine (Lys), acting in a dominant negative fashion. This mutation is confined to Orientals. Acetaldehyde oxidation is strikingly impaired in individuals with ALDH2*2 allele. ALDH2 deficiency is associated with increased the risk of cancer of the oral cavity, pharynx, larynx and esophagus.
  • Hepatitis viruses are known to increase the risk of liver cancer.
  • Epidemiological surveys are considered to support that ALDH2 deficiency is associated with increased the risk of liver cancer of alcohol drinkers with or without hepatitis viruses.
  • Our supplement mix accelerates the metabolism of alcohol and acetaldehyde. This mixture decreases the concentration of blood acetaldehyde after drinking. Therefore, our supplement is expected to decrease the risk of liver cancer for alcohol drinkers, especially those who have ALDH2*2 allele.
  • the present invention particularly solves the problem of a long impact of an accumulation of acetaldehyde after rapid alcohol degradation i.e. alcohol metabolism as may occur in most people of Non-Caucasian type genetic structure.
  • the particular food composition or dietary supplementation is considered to be appropriate to reduce a peak of excess acetaldehyde entering the blood stream and is intended to lower the risk of damage to vital organs and functions of the human body, and in this connection also lowers the risk of liver cancer.
  • the niacin-fraction (Vitamin B3) included in the composition functions as nicotinamide adenine dinucleotide (NAD), which is effective towards a coenzyme to alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).
  • NAD nicotinamide adenine dinucleotide
  • ADH alcohol dehydrogenase
  • ADH alcohol dehydrogenase
  • ADH aldehyde dehydrogenase
  • the composition also includes Pantotheic acid.
  • Pantotheic acid functions as coenzyme A (CoA), which is considered necessary to metabolize acetic acid.
  • Acetic acid is activated in conjugation with CoA to form acetyl-CoA, which is metabolized in TCA cycle.
  • elimination of a product (acetic acid) is effective towards an acceleration of the metabolism of a substrate (acetaldehyde).
  • this food composition or supplements should be taken about 5 minutes prior to consumption of alcohol and in case of high alcohol consumption again whilst consuming alcohol.
  • the mass of the food composition taken by the consumer should be in the range of about 70 to 120% of the mass of the alcohol included in the consumed drinks.
  • a standard dose might include about 10. Og dextrose, 1.Og Vitamin C, 1.5g L-glutamine, 500mg cysteine, 40mg riboflavin, 100 mg succinic acid, 100 mg fumaric acid, 60mg coenzyme QlO, and about 10 mg Niacin (Vitamin B3).
  • the relation of the components of the composition is oriented towards the above given relation.
  • the overall dosage may be adapted to the body mass weight of the consumer.
  • the particular food composition, or dietary supplementation is intended to prevent too much acetaldehyde passing into the mitochondrial matrix and to suppress self- blockade of the enzymatic activity of ALDH and thus facilitate its the decomposition of acetaldehyde.
  • the physiological risks in connection with alcohol consumption may therefore be significantly reduced by the use of the food composition according to the present invention, as this food composition or dietary supplementation facilitates in a synergetic manner an early decrease of the level of acetaldehyde after drinking and simultaneously provides a protective effect in respect of the suppression of the generation of free radicals.
  • Said food composition or dietary supplementation is preferably in such a form, preferably as ingredients of a kind of aperitif, that it allows the food composition to be consumed within a restaurant or a bar prior to consuming alcoholic drinks.
  • a dosage for a person with a body weight of about 80 kg includes a dextrose fraction of approx. 75%, wherein the said dosage may have an overall weight of about 10 to 15, preferably 13.3g.
  • Such a dosage is to provide a considerable moderation in degrading about 18ml alcohol.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same, includes a dextrose fraction of about 75.2 mass%, i.e. a quantity of dextrose in the range from 7.2 to 12.8g, preferably 10.0 g within a dose of 13,3g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a Vitamin C fraction of about 7.5 mass% i.e a quantity of Vitamin C in the range from 0.78 to 1.18 g, preferably 1.Og, within a dose of 13.3g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a L-glutamine fraction of about 11.27 mass%, i.e. a quantity of said L-glutamine fraction in the range from 1.23 to 1.7 g, preferably 1.5g, within a dose of 13.3g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a cysteine fraction of about 3.76 mass%, i.e. a quantity of said cysteine fraction in the range from 460 to 540 mg, preferably 500mg, within a dose of 13.3g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a riboflavin fraction of about 0.30 mass% i.e. a quantity of said riboflavin in the range from 32 to 48 mg, preferably 40mg, within a dose of 13.3g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a succinic acid (Bernsteinsaure) fraction of about 0.752 mass%, i.e. a quantity of said succinic acid in the range from 90 to 1 10 mg, preferably lOOmg, within a dose of 133g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a fumaric acid (Fumarsaure) fraction of about 0.752 mass%, i.e. a quantity of said fumaric acid in the range from 90 to 110 mg, preferably lOOmg, within a dose of 13.3g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a coenzyme fraction of about 0,451 mass%, i.e. a quantity of said coenzyme fraction in the range from 50 to 70 mg, preferably 60mg, within a dose of 13.3g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same is in the form of tablets.
  • each tablet is so shaped and dimensioned that it allows said tablet to be easily swallowed.
  • said tablets are in such a form that one dosage includes a plurality of those tablets.
  • the tablets may be accommodated within a dosage receptacle which includes a number of those tablets. It is possible for the food composition to be in the form of small tablets or balls, and to keep same in a small tube, while the volume of the food composition taken by the consumer can be determined with respect to the volume of alcohol which is expected to be consumed.
  • the food composition or dietary supplementation may also be in a form similar to sugar-cubes, or might be in the form of cryopowder.
  • the food composition or dietary supplementation may be separated into separate subunits. It is possible to provide one unit, for example a capsule including the Vitamin C fraction, cysteine, riboflavin, succinic acid, fumaric acid and coenzyme QlO, whilst most of the dextrose fraction is kept in separate units, capsules, tablets or the like. It is possible to add further substances such as fruit juice extracts, curcuma, tannin, a powder of Panax notoginseng, and Vinca rosea in suitable amounts. Oolong tea, aloe vera and spiral water algae might also be added.
  • the food-composition or dietary supplementation may also be in the form of a liquid, in particular a sirup-type liquid. It is possible to provide the food composition in the appearance of a soft drink in a small bottle.
  • Glucose is rapidly oxidised in the cytosol of liver cells using the same cytosol NAD+ pool used by ethanol to be converted into acetaldehyde. Because the amount of cytosolic NAD+ is limited and can only constantly be reproduced from NADH+H much less acetaldehyde accumulates.
  • the second achievement is also believed to be achieved by the intake of a large dose of glucose.
  • Glucose augments the enzymatic activity of ADH as well as of ALDH.
  • a large glucose load occurs in the cytosol of liver cells then there is no possibility that the acetaldehyde reaches levels which could lead to inactivation of ALDH or to mitochondrial destruction.
  • Riboflavin will quickly be transformed to FMN, which together with coenzyme Qio is the determining substance for the speed of the reoxidation of NADH+H + to NAD + in the mitochondrial matrix.
  • Acetaldehyde needs NAD+ when it is metabolised to acetic acid.
  • NAD + is transformed into NADH+H + .
  • NADH+H + has to be re-transformed into NAD + to serve again for acetaldehyde decomposition.
  • coenzyme Qi 0 makes also sense because its level decreases in the human body with progressing age.
  • the activation of the Krebs (citrate) cycle is believed to be achieved by the inclusion of succinic acid and fumaric acid. Both substances activate the second half of the citrate cycle and thereby activate the aerobic oxidation process in mitochondria.
  • L-glutamine helps to speed up the mitochondria-cytosolic malate- asparate shuttle, which plays a key role in the course of intoxication by acetaldehyde. It also speeds up the succinate oxidation process by preventing oxalic and acetic inhibition of succinate dehydrogenase.
  • cysteine Ascorbic acid and also of L-glutamine.
  • Cysteine should provide a strong anti-oxidant effect as well as ascorbic acid.
  • the human body transforms cysteine to gluthatione which specially protects against the toxic effects of acetaldehyde. To reach an optimal level of gluthatione and to avoid cysteine being transformed to cystine, it is important to combine cysteine with glutamine and give twice as much ascorbic acid as cysteine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition, notamment une composition alimentaire, ou bien un complément diététique qui est actif en matière de support et/ou de modération de processus de dégradation d‘alcool dans le corps humain. La présente invention concerne en particulier le problème de dégradation rapide d’alcool c’est-à-dire le métabolisme de l’alcool tel qu’il peut se produire chez la plupart des sujets de structure génétique de type non caucasien. Dans cette perspective, un objet de la présente invention entend proposer des solutions permettant de réduire le stress physiologique lié à la consommation d’alcool, notamment chez les sujets ayant une prédisposition à une dégradation rapide de l’alcool. Selon la présente invention cet objet est satisfait par une composition alimentaire ou bien un complément diététique comprenant les substances suivantes: dextrose, Vitamine C, Cystéine de L-glutamine, riboflavine, acide succinique, acide fumarique, niacine et coenzyme Q10, toutes les substances dans les doses adéquates du point de vue physiologique notamment. La composition permet de réduire les risques de cancer du foie induit par l’alcool.
PCT/EP2005/009151 2005-07-29 2005-08-24 Composition réduisant les risques de cancer du foie induit par l’alcool WO2007016953A1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
JP2008523251A JP5371428B2 (ja) 2005-07-29 2006-07-27 アルコール代謝を和らげる、およびアルコール誘発性疾患のリスクを減少させるための組成物
KR1020077028054A KR101562271B1 (ko) 2005-07-29 2006-07-27 알콜대사를 완화하고 알콜유도성 질환의 위험을 감소하기위한 조성물
PCT/EP2006/007466 WO2007017139A1 (fr) 2005-07-29 2006-07-27 Composition destinée à modérer le métabolisme de l’alcool et à réduire le risque de maladies induites par l’alcool
AU2006278823A AU2006278823B2 (en) 2005-07-29 2006-07-27 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
EP06762860A EP1909600B1 (fr) 2005-07-29 2006-07-27 Composition destinée à modérer le métabolisme de l'alcool et à réduire le risque de maladies induites par l'alcool
CA2611389A CA2611389C (fr) 2005-07-29 2006-07-27 Composition destinee a moderer le metabolisme de l'alcool et a reduire le risque de maladies induites par l'alcool
ES06762860T ES2386460T3 (es) 2005-07-29 2006-07-27 Composición para moderar el metabolismo del alcohol y para reducir el riesgo de enfermedades inducidas por el alcohol
KR20137031344A KR101487848B1 (ko) 2005-07-29 2006-07-27 알콜대사를 완화하고 알콜유도성 질환의 위험을 감소하기 위한 조성물
US11/997,127 US8580750B2 (en) 2005-07-29 2006-07-27 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
DK06762860.2T DK1909600T3 (da) 2005-07-29 2006-07-27 Sammensætning til moderering af alkoholmetabolisme og til at reducere risikoen for alkoholforårsagede sygdomme
PL06762860T PL1909600T3 (pl) 2005-07-29 2006-07-27 Kompozycja spowalniająca metabolizm alkoholu i ograniczająca ryzyko chorób wywołanych alkoholem
AT06762860T ATE554663T1 (de) 2005-07-29 2006-07-27 Zusammensetzung zur steuerung des alkohol metabolismus und zur reduktion des risikos von alkoholbedingten krankheiten
UAA200800602A UA94713C2 (uk) 2005-07-29 2006-07-27 Композиція для стримування метаболізму алкоголю та для зменшення ризику спричинених алкоголем захворювань
EA200800427A EA012753B1 (ru) 2005-07-29 2006-07-27 Композиция для сдерживания алкогольного метаболизма и для уменьшения риска заболеваний, вызванных алкоголем
PT06762860T PT1909600E (pt) 2005-07-29 2006-07-27 Composição para moderar o metabolismo do álcool e para reduzir o risco de doenças induzidas pelo álcool
SI200631337T SI1909600T1 (sl) 2005-07-29 2006-07-27 Zmes za nadzor metabolizma alkohola in za zmanjšanje nevarnosti z alkoholom induciranih bolezni
HK08110628.1A HK1117709A1 (en) 2005-07-29 2008-09-24 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
HRP20120489TT HRP20120489T1 (hr) 2005-07-29 2012-06-12 Pripravak za ublažavanje metabolizma alkohola i za smanjivanje rizika od bolesti uzrokovanih alkoholom
JP2013091972A JP5785581B2 (ja) 2005-07-29 2013-04-25 アルコール代謝を和らげる、およびアルコール誘発性疾患のリスクを減少させるための組成物
US14/058,388 US9402849B2 (en) 2005-07-29 2013-10-21 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05016563 2005-07-29
EP05016563.8 2005-07-29

Publications (1)

Publication Number Publication Date
WO2007016953A1 true WO2007016953A1 (fr) 2007-02-15

Family

ID=36021900

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2005/009151 WO2007016953A1 (fr) 2005-07-29 2005-08-24 Composition réduisant les risques de cancer du foie induit par l’alcool
PCT/EP2005/009153 WO2007016955A1 (fr) 2005-07-29 2005-08-24 Composition modérant le métabolisme de l’alcool

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/009153 WO2007016955A1 (fr) 2005-07-29 2005-08-24 Composition modérant le métabolisme de l’alcool

Country Status (1)

Country Link
WO (2) WO2007016953A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057905A1 (fr) * 2007-11-12 2009-05-13 TIMA Foundation Composition de modération des niveaux de triglycéride et de cholestérol
WO2012095509A1 (fr) * 2011-01-14 2012-07-19 Tima Foundation Composition visant à accélérer le métabolisme de l'alcool et à réduire le risque de maladies induites par l'alcool
CN102946898A (zh) * 2010-06-19 2013-02-27 天野酶株式会社 口腔内乙醛降低剂
WO2013078371A2 (fr) 2011-11-22 2013-05-30 The Johns Hopkins University Procédés et compositions pour réduire la toxicité de l'alcool
WO2016016391A1 (fr) * 2014-07-30 2016-02-04 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Agents destinés à être utilisés dans le traitement du cancer du foie et du pancréas
US10143669B2 (en) * 2015-01-23 2018-12-04 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids in cancer prevention
CN114891808A (zh) * 2022-06-21 2022-08-12 珠海丽凡达生物技术有限公司 编码ALDH2多肽的mRNA分子、应用及mRNA药物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017212113A1 (fr) * 2016-06-06 2017-12-14 Catapult Cat Oy Combinaison de l-cystéine, d'acide ascorbique et de vitamine b3 destinée à traiter la xylostomiase

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2029220A (en) * 1978-09-04 1980-03-19 Otsuka Pharma Co Ltd Amino acid solutions for patients with cancers
RU2012350C1 (ru) * 1993-05-17 1994-05-15 Александр Михайлович Шепеленко Средство для снятия алкогольного опьянения
EP0652012A1 (fr) * 1989-03-27 1995-05-10 Albert Naito Combinaison de sucres avec des acides aminés et autres composés
FR2748935A1 (fr) * 1996-05-23 1997-11-28 Clergeaud Jean Solution buvable favorisant la baisse du taux d'alcoolemie
WO2001085178A1 (fr) * 2000-05-08 2001-11-15 N.V. Nutricia Preparation nutritionnelle comprenant du ribose et de l'acide folique, et utilisation medicale associee
US20020006910A1 (en) * 2000-05-18 2002-01-17 Dmitri Miasnikov Means for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome and a method for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome by using this means
EP1195159A1 (fr) * 2000-10-09 2002-04-10 Rath, Matthias, Dr. med. Combinaison thérapeutique d'ascorbate avec de la lysine ou l'arginine pour la prévention et le traitement du cancer
WO2003006073A1 (fr) * 2001-07-10 2003-01-23 Penam Investments Pty Ltd Preparation et ses utilisations pour combattre la xylostomiase
EP1304046A1 (fr) * 2001-10-18 2003-04-23 LOTTE CONFECTIONERY CO., Ltd. Théobromine ayant une action anticarcinogénique
WO2004037018A1 (fr) * 2002-10-23 2004-05-06 Quercegen Holdings Llc Composition pour ameliorer la performance physique
RU2240789C1 (ru) * 2003-12-24 2004-11-27 Закрытое акционерное общество "НПО ПЦ БИОФИЗИКА" Средство, обладающее гепатопротекторными свойствами, для снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома
DE10326822A1 (de) * 2003-06-11 2005-01-05 Herzpharma Vita-Check Diagnosegeräte GmbH Mittel zur Nahrungsergänzung, dieses Mittel enthaltende pharmazeutische Präparate und Verwendungen des Mittels
WO2005077464A1 (fr) * 2004-02-17 2005-08-25 Matuschka-Greinffenclau Markus Composition ralentissant le metabolisme de l'alcool

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1058914A (zh) * 1991-03-16 1992-02-26 肖宏生 酒液多功能口服液

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2029220A (en) * 1978-09-04 1980-03-19 Otsuka Pharma Co Ltd Amino acid solutions for patients with cancers
EP0652012A1 (fr) * 1989-03-27 1995-05-10 Albert Naito Combinaison de sucres avec des acides aminés et autres composés
RU2012350C1 (ru) * 1993-05-17 1994-05-15 Александр Михайлович Шепеленко Средство для снятия алкогольного опьянения
FR2748935A1 (fr) * 1996-05-23 1997-11-28 Clergeaud Jean Solution buvable favorisant la baisse du taux d'alcoolemie
WO2001085178A1 (fr) * 2000-05-08 2001-11-15 N.V. Nutricia Preparation nutritionnelle comprenant du ribose et de l'acide folique, et utilisation medicale associee
US20020006910A1 (en) * 2000-05-18 2002-01-17 Dmitri Miasnikov Means for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome and a method for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome by using this means
EP1195159A1 (fr) * 2000-10-09 2002-04-10 Rath, Matthias, Dr. med. Combinaison thérapeutique d'ascorbate avec de la lysine ou l'arginine pour la prévention et le traitement du cancer
WO2003006073A1 (fr) * 2001-07-10 2003-01-23 Penam Investments Pty Ltd Preparation et ses utilisations pour combattre la xylostomiase
EP1304046A1 (fr) * 2001-10-18 2003-04-23 LOTTE CONFECTIONERY CO., Ltd. Théobromine ayant une action anticarcinogénique
WO2004037018A1 (fr) * 2002-10-23 2004-05-06 Quercegen Holdings Llc Composition pour ameliorer la performance physique
DE10326822A1 (de) * 2003-06-11 2005-01-05 Herzpharma Vita-Check Diagnosegeräte GmbH Mittel zur Nahrungsergänzung, dieses Mittel enthaltende pharmazeutische Präparate und Verwendungen des Mittels
RU2240789C1 (ru) * 2003-12-24 2004-11-27 Закрытое акционерное общество "НПО ПЦ БИОФИЗИКА" Средство, обладающее гепатопротекторными свойствами, для снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома
WO2005077464A1 (fr) * 2004-02-17 2005-08-25 Matuschka-Greinffenclau Markus Composition ralentissant le metabolisme de l'alcool

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199505, Derwent World Patents Index; Class B05, AN 1995-034579, XP002373928 *
DATABASE WPI Section Ch Week 200506, Derwent World Patents Index; Class B05, AN 2005-055600, XP002373159 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057905A1 (fr) * 2007-11-12 2009-05-13 TIMA Foundation Composition de modération des niveaux de triglycéride et de cholestérol
WO2009062910A1 (fr) * 2007-11-12 2009-05-22 Tima Foundation Composition pour modérer les taux de triglycérides et de cholestérol
CN102946898A (zh) * 2010-06-19 2013-02-27 天野酶株式会社 口腔内乙醛降低剂
WO2012095509A1 (fr) * 2011-01-14 2012-07-19 Tima Foundation Composition visant à accélérer le métabolisme de l'alcool et à réduire le risque de maladies induites par l'alcool
EP2782583A4 (fr) * 2011-11-22 2016-04-13 Univ Johns Hopkins Procédés et compositions pour réduire la toxicité de l'alcool
KR20140106549A (ko) * 2011-11-22 2014-09-03 더 존스 홉킨스 유니버시티 알코올 독성을 감소시키기 위한 방법들 및 조성물들
CN104520311A (zh) * 2011-11-22 2015-04-15 约翰霍普金斯大学 用于降低酒精毒性的方法和组合物
WO2013078371A2 (fr) 2011-11-22 2013-05-30 The Johns Hopkins University Procédés et compositions pour réduire la toxicité de l'alcool
CN104520311B (zh) * 2011-11-22 2018-03-13 约翰霍普金斯大学 用于降低酒精毒性的方法和组合物
KR102002147B1 (ko) 2011-11-22 2019-07-19 더 존스 홉킨스 유니버시티 알코올 독성을 감소시키기 위한 방법들 및 조성물들
WO2016016391A1 (fr) * 2014-07-30 2016-02-04 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Agents destinés à être utilisés dans le traitement du cancer du foie et du pancréas
US10143669B2 (en) * 2015-01-23 2018-12-04 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids in cancer prevention
US10231941B2 (en) 2015-01-23 2019-03-19 Temple University—Of The Commonwealth System of Higher Educaton Use of short chain fatty acids in cancer prevention
AU2019201799B2 (en) * 2015-01-23 2020-10-15 Helena M.G.P.V. Reis Use of short chain fatty acids in cancer prevention
US11963938B2 (en) 2015-01-23 2024-04-23 Temple University-Of The Commonwealth System Of Higher Education Use of short chain fatty acids in cancer prevention
CN114891808A (zh) * 2022-06-21 2022-08-12 珠海丽凡达生物技术有限公司 编码ALDH2多肽的mRNA分子、应用及mRNA药物
CN114891808B (zh) * 2022-06-21 2023-10-27 珠海丽凡达生物技术有限公司 编码ALDH2多肽的mRNA分子、应用及mRNA药物

Also Published As

Publication number Publication date
WO2007016955A1 (fr) 2007-02-15

Similar Documents

Publication Publication Date Title
US9402849B2 (en) Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
AU2005211936B2 (en) Alcohol metabolism moderating composition
Dasgupta Alcohol and its biomarkers: clinical aspects and laboratory determination
JP2007522254A6 (ja) アルコール代謝調節組成物
WO2007016953A1 (fr) Composition réduisant les risques de cancer du foie induit par l’alcool
WO2007016949A1 (fr) Composition réduisant les risques de neuropathie induite par l’alcool
CN114246941A (zh) 一种具有预防宿醉和解酒保肝的组合物及其应用
WO2012095509A1 (fr) Composition visant à accélérer le métabolisme de l'alcool et à réduire le risque de maladies induites par l'alcool
WO2007016954A1 (fr) Composition réduisant les risques de cancer du sein induit par l’alcool ou les médicaments
WO2007016950A1 (fr) Composition réduisant les risques de maladie neurodégénérative induite par l’alcool
WO2007016952A1 (fr) Composition réduisant les risques de cancer de l’oesophage ou de l’oropharyngolaryngée induit par l’alcool
CN109562090A (zh) 用于治疗宿醉的l-半胱胺酸、抗坏血酸和维生素b3的组合物
WO2007016951A1 (fr) Composition réduisant les risques de cancer du pancréas induit par l’alcool

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05775870

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载